Shield Therapeutics and Norgine have entered into an exclusive licence agreement in Europe, Australia and New Zealand, under which Norgine will commercialise Feraccru, Shield’s approved product for the treatment of iron deficiency in adults.
20 Sep 2018
06 Jun 2017
Perrigo said its current CEO John Hendrickson is retiring and it has started a search for a replacement.
13 Feb 2017
Sanofi has agreed to divest five of its over-the-counter consumer healthcare products in Europe to French pharma firm Ipsen for €83m.